The strong sales of Rezdiffra indicate a successful product launch, which is a positive indicator for Madrigal Pharmaceuticals. The mention of buyout discussions suggests potential acquisition interest, which could drive the stock price up. Additionally, the potential for combination therapies and a future EU launch in 2025 provide further growth opportunities, making the stock attractive to investors.